Posted by admin on Apr 14th, 2022
Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Profitability
This table compares Voyager Therapeutics and Surface Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Voyager Therapeutics | -190.30% | -66.35% | -34.52% |
| Surface Oncology | -2,920.92% | -56.34% | -39.26% |
Analyst Ratings
This is a summary of current recommendations and price targets for Voyager Therapeutics and Surface Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Voyager Therapeutics | 0 | 2 | 3 | 0 | 2.60 |
| Surface Oncology | 0 | 0 | 3 | 0 | 3.00 |
Voyager Therapeutics currently has a consensus target price of $7.20, suggesting a potential downside of 17.43%. Surface Oncology has a consensus target price of $13.00, suggesting a potential upside of 394.30%. Given Surface Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Surface Oncology is more favorable than Voyager Therapeutics.
Earnings & Valuation
This table compares Voyager Therapeutics and Surface Oncology’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Voyager Therapeutics | $37.42 million | 8.88 | -$71.20 million | ($1.90) | -4.59 |
| Surface Oncology | $2.69 million | 45.91 | -$78.49 million | ($1.77) | -1.49 |
Voyager Therapeutics has higher revenue and earnings than Surface Oncology. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Surface Oncology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Voyager Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Surface Oncology has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Institutional and Insider Ownership
63.6% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 60.7% of Surface Oncology shares are held by institutional investors. 25.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 15.0% of Surface Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Surface Oncology beats Voyager Therapeutics on 7 of the 13 factors compared between the two stocks.
About Voyager Therapeutics (Get Rating)
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
About Surface Oncology (Get Rating)
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Voyager Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Voyager Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
You might be interested in:
